Drug Profile
Genz 644282
Alternative Names: Genz-644282Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours